高强度聚焦超声睫状体成形术治疗青光眼的疗效和安全性。
Efficacy and safety of high-intensity focused ultrasound cyclo-plasty in glaucoma.
机构信息
Department of Ophthalmology, Affiliated Foshan Hospital, Southern Medical University, Foshan, 528000, China.
出版信息
BMC Ophthalmol. 2022 Oct 7;22(1):401. doi: 10.1186/s12886-022-02622-5.
BACKGROUND
High-intensity focused ultrasound cyclo-plasty (UCP) is a recently developed glaucoma surgery. This study collected and analysed the clinical data of patients who underwent UCP to observe the efficacy and safety of this surgery in Chinese glaucoma patients.
METHODS
This was a retrospective study. The clinical data of all the patients who underwent UCP at Affiliated Foshan Hospital, Southern Medical University, were collected and analysed to evaluate the efficacy and safety of UCP. The main outcome measure was intraocular pressure, and the secondary outcome measures were best corrected visual acuity (logMAR) and complications.
RESULTS
Fifty-eight patients (61 eyes) were recruited for this study. IOP was dramatically decreased during the 12 months after UCP (p<0.05). The median IOP reduction during the 18 months post-procedure was more than 30%. The greatest reduction was at 1 month post-UCP (60.86%). The qualified success rate was more than 60% during the 18-month follow-up (Fig. 1). Poor follow up was found after 6-month post-UCP. The highest success rate was obtained at 7 days post-UCP (94.55%). No statistically significant decrease in BCVA in the vison group was observed at the follow-up visits, except for 1 day post-UCP. There was a statistically significant reduction in the use of IOP lowering medications during the 6 months post-UCP. No severe complications occurred.
CONCLUSION
UCP is a safe and effective procedure for primary and refractive glaucoma at least during the 6 months post-UCP procedure. Studies with longer follow-up time and better follow up are needed to further confirm the long-term efficacy and safety of UCP in Chinese glaucoma patients.
背景
高强度聚焦超声睫状体成形术(UCP)是一种新开发的青光眼手术。本研究收集并分析了接受 UCP 的患者的临床资料,以观察该手术在中国青光眼患者中的疗效和安全性。
方法
这是一项回顾性研究。收集并分析了南方医科大学附属佛山医院所有接受 UCP 的患者的临床资料,以评估 UCP 的疗效和安全性。主要观察指标为眼压,次要观察指标为最佳矫正视力(logMAR)和并发症。
结果
本研究共纳入 58 例(61 只眼)患者。UCP 后 12 个月眼压显著降低(p<0.05)。术后 18 个月眼压中位数降低超过 30%。最大降幅出现在 UCP 后 1 个月(60.86%)。18 个月随访时,合格成功率超过 60%(图 1)。UCP 后 6 个月后随访不佳。UCP 后 7 天成功率最高(94.55%)。除 UCP 后 1 天外,视力组在随访期间的 BCVA 未见明显下降。UCP 后 6 个月内,眼压降低药物的使用量有统计学意义的减少。未发生严重并发症。
结论
UCP 是一种安全有效的原发性和屈光性青光眼治疗方法,至少在 UCP 术后 6 个月内是如此。需要进行更长时间和更好随访的研究,以进一步证实 UCP 在我国青光眼患者中的长期疗效和安全性。
相似文献
BMC Ophthalmol. 2022-10-7
Acta Ophthalmol. 2023-5
Graefes Arch Clin Exp Ophthalmol. 2017-3
Semin Ophthalmol. 2023-7
J Glaucoma. 2023-5-1
引用本文的文献
Int J Ophthalmol. 2025-3-18
Int J Ophthalmol. 2023-8-18
本文引用的文献
Invest Ophthalmol Vis Sci. 2022-6-1
Int Ophthalmol. 2021-9